_____________________________________________________________________________________________________ *Corresponding author: E-mail: Abdul_samad93@hotmail.com; Journal of Pharmaceutical Research International 33(50A): 154-158, 2021; Article no.JPRI.73208 ISSN: 2456-9119 (Past name: British Journal of Pharmaceutical Research, Past ISSN: 2231-2919, NLM ID: 101631759) Coronavirus - Drug Discovery and Therapeutic Options Abdul Samad Tayyab a* , Maria Qurban b , Maryam Mazhar c , Zaid Tayyab d , Mariam Tahir e and Zain Tayyab f a Dental Surgeon THQ Haveli Lakha, Okara, Pakistan. b Dental Surgeon THQ Hospital Depalpur, Okara, Pakistan. c Medical Officer at BHU Jjallo, Lahore, Pakistan. d MO at Mayo Hospital, Lahore, Pakistan. e MO at Ittefaq Hospital, Lahore, Pakistan. f Senior Registrar at Sir Ganga Ram Hospital, Lahore, Pakistan. Authors’ contributions This work was carried out in collaboration among all authors. All authors read and approved the final manuscript. Article Information DOI: 10.9734/JPRI/2021/v33i50A33391 Editor(s): (1) Dr. Anil Kumar, Devi Ahilya University, India. (2) Dr. Mohamed AliAbdel-Rahman, Al-Azhar University, Egypt. (3) Dr. Fernando José Cebola Lidon, Universidade Nova de Lisboa, Portugal. (4) Dr. Giuseppe Murdaca, University of Genoa, Italy. Reviewers: (1) Arifa Akram, National Institute of Laboratory Medicine and Referral Center, Bangladesh. (2) IliyasIliyasu A A Ibrahim, Bauchi State University Gadau, Nigeria. (3) Israa Hashim Saadoon, Tikrit University, Iraq. Complete Peer review History: https://www.sdiarticle4.com/review-history/73208 Received 25 September 2021 Accepted 01 November 2021 Published 15 November 2021 ABSTRACT COVID-19 is basically a medium size RNA virus and the nucleic acid is about 30 kb long, positive in sense, single stranded and polyadenylated. The RNA which is found in this virus is the largest known RNA and codes for a large polyprotein. In addition, coronaviruses are capable of genetic recombination if 2 viruses infect the same cell at the same time. SARS-CoV emerged first in southern China and rapidly spread around the globe in 2002–2003. In November 2002, an unusual epidemic of atypical pneumonia with a high rate of nosocomial transmission to health-care workers occurred in Foshan, Guangdong, China. In March 2003, a novel CoV was confirmed to be the causative agent for SARS, and was thus named SARS-CoV. Despite the report of a large number of virus-based and host-based treatment options with potent in vitro activities for SARS and MERS, Short Communication